Harvard pens Astellas research deal, vowing to push on despite pandemic

With COVID-19 still sweeping across the U.S. and daily cases and deaths making for grim reading, biomedical R&D deals are not an easy sell.

But researchers at Harvard University and Japanese pharma Astellas are not letting a major pandemic and lockdown get in the way of science: The pair have announced a new research tie-up focused on “multiple, multi-year research projects initiated by faculty at Harvard, focused on the research and development of innovative therapeutics and technologies of mutual interest.”